Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. Co. is engaged in the discovery and development of treatments for neurodegenerative diseases. Co. is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Co.'s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The AMLX average annual return since 2022 is shown above.
The Average Annual Return on the AMLX average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AMLX average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMLX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|